Lynavoy is a drug owned by Glaxosmithkline Llc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 06, 2031. Details of Lynavoy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9040518 | Chemical Compounds |
Sep, 2031
(5 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Lynavoy is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Lynavoy's family patents as well as insights into
ongoing legal events
on those patents.
Lynavoy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lynavoy's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 06, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lynavoy Generics:
There are no approved generic versions for Lynavoy as of now.
About Lynavoy
Lynavoy is a drug owned by Glaxosmithkline Llc. Lynavoy uses Linerixibat as an active ingredient. Lynavoy was launched by Glaxosmithkline in 2026.
Approval Date:
Lynavoy was approved by FDA for market use on 17 March, 2026.
Active Ingredient:
Lynavoy uses Linerixibat as the active ingredient. Check out other Drugs and Companies using Linerixibat ingredient
Dosage:
Lynavoy is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG | TABLET | Prescription | ORAL |